IP Library › Granted Patent US 10,980,849
Granted Patent B2
US 10,980,849 · App. 16/202,274 · Granted Apr 20, 2021

Brain function improving agent

Inventors: Yodai Kobayashi (Zama, JP); Tetsuya Kuhara (Zama, JP); Kanetada Shimizu (Zama, JP); Takumi Sato (Zama, JP)
Assignee: MORINAGA MILK INDUSTRY CO., LTD.
A61K35/745A23L33/135A61P25/18A61P25/24A61P25/28C12N1/20A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,849
App. No.
16/202,274
Granted
Apr 20, 2021
Kind
B2
Abstract

A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve -containing cultured material is provided.

Claims (8)

1. A method for prevention, treatment, and/or improvement of symptoms or diseases resulting from reduced brain function in a subject, comprising a step of administering a Bifidobacterium breve and/or a cultured material comprising Bifidobacterium breve to the subject,

wherein said reduced brain function is a result of said subject having a condition selected from the group consisting of dementia, depression, schizophrenia, delirium, and combinations thereof, and

wherein the Bifidobacterium breve is Bifidobacterium breve MCC1274 (FERM BP-11175).

2. A method of prevention, treatment, and/or improvement of symptoms or diseases resulting from a reduced brain function in a subject, comprising a step of administering a food or beverage product comprising Bifidobacterium breve and/or a cultured material comprising Bifidobacterium breve to the subject,

wherein said reduced brain function is a result of said subject having a condition selected from the group consisting of dementia, depression, schizophrenia, delirium, and combinations thereof, and

wherein the Bifidobacterium breve is Bifidobacterium breve MCC1274 (FERM BP-11175).

3. The method of claim 1 , wherein said dementia is selected from the group consisting of Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, cerebrovascular dementia, and combinations thereof.

4. The method of claim 2 , wherein said dementia is selected from the group consisting of Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, cerebrovascular dementia, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2018
From: KOBAYASHI, YODAI; KUHARA, TETSUYA; SHIMIZU, KANETADA; SATO, TAKUMI
To: MORINAGA MILK INDUSTRY CO., LTD.
Reel/Frame 047854/0011 →
Priority Claims (1)
JP JP2016-108944 · May 31, 2016 · national
Continuity (2)
Continuation PCTJP2017020173 · May 31, 2017
Related Publication 20190083549A1 · Mar 21, 2019